Stephen G Maher
Overview
Explore the profile of Stephen G Maher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
932
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kane L, Mellotte G, Mylod E, Dowling P, Marcone S, Scaife C, et al.
Sci Rep
. 2025 Jan;
15(1):129.
PMID: 39747972
Integration of multi-omic data for the purposes of biomarker discovery can provide novel and robust panels across multiple biological compartments. Appropriate analytical methods are key to ensuring accurate and meaningful...
2.
Murchu M, Lin X, Tutty M, Cahill C, Miller I, Jensen L, et al.
Cancer Lett
. 2024 Dec;
611():217406.
PMID: 39716484
Radiotherapy is used to treat over 50 % of cancer patients. It is often used in combination with surgery, chemotherapy, and immunotherapy, for cancers of the breast, lung, oesophagus, and...
3.
Marcone S, Spadavecchia J, Khan M, Vella G, OConnell F, Pendino M, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682192
Methods: To overcome these limitations, pyrazinib was conjugated with gold nanoparticles (AuNP-P3), creating a novel formulation designed to enhance solubility, maintain bioactivity, and enable targeted delivery to tumour sites. Results:...
4.
Davern M, Gaughan C, O Connell F, Moran B, Mylod E, Sheppard A, et al.
Front Immunol
. 2023 Jun;
14:1150754.
PMID: 37359545
Introduction: This timely study assesses the immunosuppressive effects of surgery on cytotoxic Th1-like immunity and investigates if immune checkpoint blockade (ICB) can boost Th1-like immunity in the perioperative window in...
5.
Cannon A, Maher S, Lynam-Lennon N
Methods Mol Biol
. 2023 May;
2645:139-152.
PMID: 37202615
Radiation therapy is a cornerstone of cancer treatment worldwide. Unfortunately, in many cases, it does not control tumor growth, and many tumors display treatment resistance. The molecular pathways leading to...
6.
Kane L, Mellotte G, Mylod E, OBrien R, OConnell F, Buckley C, et al.
Cancer Res Commun
. 2023 Mar;
2(10):1229-1243.
PMID: 36969742
Significance: In a systematic review and three-level multivariate meta-analysis, it is shown for the first time that blood-based multi-biomarker panels for the diagnosis of PDAC exhibit superior performance in comparison...
7.
Davern M, Donlon N, Sheppard A, Majcher K, O Connell F, Heeran A, et al.
J Cancer Res Clin Oncol
. 2022 Aug;
149(7):3753-3774.
PMID: 35986757
Combining immunostimulatory chemotherapies with immunotherapy is an attractive strategy to enhance treatment responses in oesophagogastric junctional adenocarcinoma (OGJ). This study investigates the immunostimulatory properties of FLOT, CROSS and MAGIC chemotherapy...
8.
McGrath J, Kane L, Maher S
Cells
. 2022 Jul;
11(15).
PMID: 35892591
Radioresistance remains a significant challenge in treating pancreatic ductal adenocarcinoma (PDAC), contributing to the poor survival rates of this cancer. MicroRNAs (miRs) are small non-coding RNA molecules that may play...
9.
Davern M, Donlon N, O Connell F, Sheppard A, Hayes C, King R, et al.
Transl Oncol
. 2022 Apr;
20:101406.
PMID: 35366537
Response rates to immune checkpoint blockade (ICB) remain low in oesophageal adenocarcinoma (OAC). Combining ICB with immunostimulatory chemotherapies to boost response rates is an attractive approach for converting 'cold' tumours...
10.
Mylod E, McKenna E, Davern M, Barr M, Donlon N, Bibby B, et al.
Clin Exp Med
. 2022 Apr;
23(2):411-425.
PMID: 35364779
The majority of oesophageal adenocarcinoma (OAC) patients do not respond to multimodal treatment regimens and face dismal survival rates. Natural killer (NK) cells are crucial anti-tumour immune cells, and this...